Imatinib has revolutionized the treatment of chronic myeloid leukaemia (CML). In 2016, generic imatinib will be introduced into the US market. We analyse the potential impact of this new product on patient care and optimal CML therapy, and comment on the effect that distorted cancer drug pricing in the USA will have on treatment for patients with limited therapeutic options.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2
Cell Death & Disease Open Access 19 August 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
NOVARTIS. Novartis Q4 and FY 2015 condensed financial report. [online], (2016).
REUTERS. Sun hopes cut-price generic Gleevec will win third of U.S. market. [online], (2016).
Padula, W. V. et al. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States. J. Natl Cancer Inst. 108, djw003 (2016).
Chhatwal, J., Mathisen, M. & Kantarjian, H. Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer 121, 3372–3379 (2015).
Institute for Clinical and Economic Review. Evaluating the value of new drugs. [online], (2015).
Larson, R. A. et al. What is the most cost-effective strategy for treating newly diagnosed chronic phase chronic myeloid leukemia (CML) after Imatinib loses patent exclusivity? Blood 124, 738 (2014).
Jones, G. H., Carrier, M. A., Silver, R. T. & Kantarjian, H. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Blood 127, 1398–1402 (2016).
Kantarjian, H., Mathisen, M. S. & Lipton, J. H. Having 'skin in the game' and allowing cross-border importation of drugs to lower high prices of cancer drugs. JAMA Oncol. 6, 729–730 (2015).
Knox, R. Cancer drug mark-ups: year of Gleevec costs $159 to make but sells for $106K. CommonHealth [online], (2015).
Beasley, D. Pfizer hikes U.S. prices for over 100 drugs on January 1. REUTERS [online], (2016).
Author information
Authors and Affiliations
Corresponding author
PowerPoint slides
Rights and permissions
About this article
Cite this article
Gorkin, L., Kantarjian, H. Generic imatinib — impact on frontline and salvage therapy for CML. Nat Rev Clin Oncol 13, 270–272 (2016). https://doi.org/10.1038/nrclinonc.2016.59
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.59
This article is cited by
-
Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches
Clinical Drug Investigation (2024)
-
On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2
Cell Death & Disease (2020)
-
Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making
Current Hematologic Malignancy Reports (2018)
